, Tracking Stock Market Picks
Enter Symbol:
Catalyst Pharmaceutical Partners, Inc. (CPRX) [hlAlert]

down 77.04 %

Catalyst Pharmaceutical Partners, Inc. (CPRX) rated Underperform by Hapoalim

Posted on: Friday,  May 29, 2009  9:25 AM ET by Hapoalim

Hapoalim rated Underperform Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) on 05/29/2009, when the stock price was $0.84. Since
then, Catalyst Pharmaceutical Partners, Inc. has gained 335.71% as of 01/22/2016's recent price of $3.66.
If you would have followed this Hapoalim's recommendation on CPRX, you would have lost 77.04% of your investment in 2429 days.

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. Its product candidate CPP-109, which is the version of the chemical compound gamma-vinyl-GABA, referred to as vigabatrin. As of December 31, 2008, the Company was conducting two clinical trials of CPP-109, one evaluating its use in the treatment of cocaine addiction, and a second evaluating its use in the treatment of methamphetamine addiction. CPP-109 has the potential to treat other addictions, including addictions to nicotine, prescription pain, medications, alcohol, and marijuana, as well as obsessive-compulsive disorders, such as obesity and compulsive gambling.

Hapoalim Securities redistributes fundamental research on Israeli growth companies written by professional analysts employed by our affiliate, Bank Hapoalim B.M. The research product has an emphasis and strength in diversified sectors, including technology, communications and pharmaceutical companies. The strength of Hapoalim's relationships with these companies allows us to provide clients with access to the managements of the companies as necessary.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/29/2009 9:25 AM Sell
as of 12/31/2009
1 Week down  -82.53 %
1 Month down  -49.35 %
3 Months down  -36.90 %
1 YTD down  -36.90 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy